These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Wang JY; Wang YH; Jao SW; Lu CY; Kuo CH; Hu HM; Hsieh JS; Chong IW; Cheng TL; Lin SR Oncol Rep; 2006 Dec; 16(6):1245-52. PubMed ID: 17089045 [TBL] [Abstract][Full Text] [Related]
25. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339 [TBL] [Abstract][Full Text] [Related]
27. Cytometric study of carcinoid tumors and their metastases. Olinici CD; Cäluser I Arch Geschwulstforsch; 1988; 58(6):403-9. PubMed ID: 3223791 [TBL] [Abstract][Full Text] [Related]
28. Identification of MEN1 mutations in sporadic enteropancreatic neuroendocrine tumors by analysis of paraffin-embedded tissue. Mailman MD; Muscarella P; Schirmer WJ; Ellison EC; O'Dorisio TM; Prior TW Clin Chem; 1999 Jan; 45(1):29-34. PubMed ID: 9895334 [TBL] [Abstract][Full Text] [Related]
29. [Mutations of the Ki-ras gene: an early event in pancreatic carcinogenesis]. Knoll MR; Singer MV Z Gastroenterol; 1994 Jul; 32(7):420-1. PubMed ID: 7975782 [No Abstract] [Full Text] [Related]
31. Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS). Boudreaux JP Endocrinol Metab Clin North Am; 2011 Mar; 40(1):163-71, ix. PubMed ID: 21349417 [TBL] [Abstract][Full Text] [Related]
32. Expression of growth factors and their receptors in neuroendocrine gut and pancreatic tumors, and prognostic factors for survival. Oberg K Ann N Y Acad Sci; 1994 Sep; 733():46-55. PubMed ID: 7978895 [No Abstract] [Full Text] [Related]
35. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552 [TBL] [Abstract][Full Text] [Related]
36. [The study of the effect of antisense oligonucleotide specific to K-ras point mutation on human pancreatic carcinoma cell PC-2]. Wang YX; Gao L; Ji ZZ Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(21):1387-90. PubMed ID: 16318775 [TBL] [Abstract][Full Text] [Related]
37. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Berković M; Cacev T; Zjacić-Rotkvić V; Kapitanović S Neuroendocrinology; 2006; 84(5):346-52. PubMed ID: 17164537 [TBL] [Abstract][Full Text] [Related]
38. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Adsay NV; Basturk O; Cheng JD; Andea AA Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479 [TBL] [Abstract][Full Text] [Related]
39. The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract. Gurevich L; Kazantseva I; Isakov VA; Korsakova N; Egorov A; Kubishkin V; Bulgakov G Cancer; 2003 Nov; 98(9):1967-76. PubMed ID: 14584081 [TBL] [Abstract][Full Text] [Related]
40. Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study. Petzmann S; Ullmann R; Halbwedl I; Popper HH Virchows Arch; 2004 Aug; 445(2):151-9. PubMed ID: 15235910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]